In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols

Pharmaceutical Development and Technology

Volumn 16, Issue 6, 2011, Pages 577-582

  Alexander, Barbara D ^a   Winkler, Thomas P ^b   Shi, Shuai ^b   Dodds Ashley, Elizabeth S ^a,c   Hickey, Anthony J ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Aerosol; Ambisome; Antifungal; Cascade impaction

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRY DEPOSITION; IN VITRO STUDY; MEDIAN AERODYNAMIC DIAMETER; NEBULIZER; PARTICLE SIZE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; AEROSOLS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE;

EID: 80755143777     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2011.591803     Document Type: Article

References (29)

1. Lyman CA, Walsh TJ. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 1992;44:9-35.
2. Herbrecht R, Denning DW, Patterson T F, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. New England Journal of Medicine 2002;347:408-415. (Pubitemid 34851833)
3. Wingard JR, Kubilis P, Lee L, Yee G, White M, Walshe L et al. Clinical signifcance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-1407. (Pubitemid 30022731)
4. Behre GF, Schwartz S, Lenz K, Ludwig WD, Wandt H, Schilling E et al. Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients. Ann Hematol 1995;71:287-291. (Pubitemid 26002066)
5. Beyer J, Barzen G, Risse G, Weyer C, Miksits K, Dullenkopf K et al. Aerosol amphotericin B for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1993;37:1367-1369. (Pubitemid 23166742)
6. Conneally E, Caferkey MT, Daly PA, Keane CT, McCann SR. Nebulized amphotericin B as prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990;5:403-406. (Pubitemid 20344122)
7. De Laurenzi A, Matteocci A, Lanti A, Pescador L, Blandino F, Papetti C. Amphotericin B prophylaxis against invasive fungal infections in neutropenic patients: A single center experience from 1980 to 1995. Infection 1996;24:361-366. (Pubitemid 26356500)
8. Dubois J, Bartter T, Gryn J, Pratter MR. Te physiologic efects of inhaled amphotericin B. Chest 1995;108:750-753.
9. Erjavec Z, Woolthuis GM, de Vries-Hospers HG, Sluiter WJ, Daenen SM, de Pauw B et al. Tolerance and efcacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients. Eur J Clin Microbiol Infect Dis 1997;16:364-368. (Pubitemid 27271824)
10. Gryn J, Goldberg J, Johnson E, Siegel J, Inzerillo J. Te toxicity of daily inhaled amphotericin B. Am J Clin Oncol 1993;16:43-46.
11. Hertenstein B, Kern WV, Schmeiser T, Stefanic M, Bunjes D, Wiesneth M et al. Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol 1994;68:21-26. (Pubitemid 24052471)
12. Myers SE, Devine SM, Topper RL, Ondrey M, Chandler C, O'Toole K et al. A pilot study of prophylactic aerosolized amphotericin B in patients at risk for prolonged neutropenia. Leuk Lymphoma 1992;8:229-233.
13. Drew RH, Dodds Ashley E, Benjamin DK Jr, Duane Davis R, Palmer SM, Perfect JR. Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients. Transplantation 2004;77:232-237. (Pubitemid 38155752)
14. Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008;46:1401-1408. (Pubitemid 351589940)
15. Monforte V, Ussetti P, López R, Gavaldà J, Bravo C, de Pablo A et al. Nebulized liposomal amphotericin B prophylaxis for Aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant 2009;28:170-175.
16. Shi S, Ashley ES, Alexander BD, Hickey AJ. Initial characterization of micafungin pulmonary delivery via two diferent nebulizers and multivariate data analysis of aerosol mass distribution profles. AAPS PharmSciTech 2009;10:129-137.
17. Christopher D, Adams W, Amann A, Bertha C, Byron PR, Doub W et al. Product Quality Research Institute evaluation of cascade impactor profles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence. AAPS PharmSciTech 2007;8:E90.
18. Hinds W. Aerosol technology: Properties, behavior, and measurement of airborne particles. 2nd ed. New York: John Wiley & Sons; 1999.
19. Sbirlea-Apiou G, Katz I, Caillibotte G, Martonen T, Yang Y. Deposition mechanics of pharmaceutical particles in human airways. In: Hickey A.J., ed. Inhalation Aerosols: Physical and Biological Basis for Terapy. New York: Informa Health Care, 2007:1-30.
20. Roth C, Gebhart J, Just-Nübling G, von Eisenhart-Rothe B, Beinhauer-Reeb I. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Infection 1996;24:354-360. (Pubitemid 26356499)
21. Diot P, Rivoire B, Le Pape A, Lemarie E, Dire D, Furet Y et al. Deposition of amphotericin B aerosols in pulmonary aspergilloma. Eur Respir J 1995;8:1263-1268.
22. Adams WP, Ahrens RC, Chen ML, Christopher D, Chowdhury BA, Conner DP et al. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report. J Aerosol Med Pulm Drug Deliv 2010;23:1-29.
23. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004;1:338-344.
24. Astellas Pharma US IDII. AmBisome® (amphotericin B liposome) for injection; package insert. 2008. Available at: http://www. astellas.us/docs/ ambisome.pdf. Accessed 18 April 2011.
25. Ruijgrok EJ, Vulto AG, Van Etten EW. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats. J Pharm Pharmacol 2000;52:619-627. (Pubitemid 30410074)
26. Lambros MP, Bourne DW, Abbas SA, Johnson DL. Disposition of aerosolized liposomal amphotericin B. J Pharm Sci 1997;86:1066-1069.
27. Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proft RT. Prophylactic efcacy of aerosolized liposomal (AmBisome) and non-liposomal (Fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother 1994;34:1001-1013.
28. Niven RW, Schreier H. Nebulization of liposomes. I. Efects of lipid composition. Pharm Res 1990;7:1127-1133.
29. Farr SJ, Kellaway IW, Parry-Jones DW, Woolfrey SG. 99m-Technetium as a marker of liposomal deposition and clearance in the human lung. International Journal of Pharmaceutics 1985;26:303-316. (Pubitemid 16228628)